Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C185146
http://purl.obolibrary.org/obo/NCIT_C185146
|
|---|---|
| Preferred Name | PLK4 Inhibitor CFI-400945 |
| Definitions |
A polo-like kinase 4 (PLK4) inhibitor with potential antineoplastic activity. Upon administration, polo-like kinase 4 inhibitor CFI-400945 selectively inhibits PLK4, which results in the disruption of mitosis and the induction of apoptosis. PLK4 inhibition also prevents cell division and inhibits proliferation of PLK4-overexpressing tumor cells. PLK4, a member of the polo family of serine/threonine kinases overexpressed in a variety of cancer cell types, plays a crucial role in the regulation of centriole duplication during the cell cycle.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A polo-like kinase 4 (PLK4) inhibitor with potential antineoplastic activity. Upon administration, polo-like kinase 4 inhibitor CFI-400945 selectively inhibits PLK4, which results in the disruption of mitosis and the induction of apoptosis. PLK4 inhibition also prevents cell division and inhibits proliferation of PLK4-overexpressing tumor cells. PLK4, a member of the polo family of serine/threonine kinases overexpressed in a variety of cancer cell types, plays a crucial role in the regulation of centriole duplication during the cell cycle. |
|---|---|
| prefLabel | PLK4 Inhibitor CFI-400945
|
| label | PLK4 Inhibitor CFI-400945
|
| Has_Salt_Form | |
| NCI_META_CUI | CL1773476
|
| code | C185146
|
| prefixIRI | NCIT:C185146
|
| in_subset | |
| Preferred_Name | PLK4 Inhibitor CFI-400945
|
| FDA_UNII_Code | TL1UD860AA
|
| Contributing_Source | FDA
|
| CAS_Registry | 1338806-73-7
|
| type | |
| subClassOf | |
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |